CD13 identifies S100A4+ immunosuppressive monocytes and predicts temozolomide benefit in glioblastoma
{{output}}
Background: Glioblastoma (GBM) is an immunologically "cold" tumor in which S100A4-driven immunosuppressive myeloid cells promote progression and resistance. However, the specific immune subpopulation that intrinsically expresse... ...
